Okay, let's tackle this question about the treatment of Zollinger-Ellison syndrome. First, I need to recall what Zollinger-Ellison syndrome (ZES) is. It's a condition caused by a gastrin-secreting tumor, usually a gastrinoma, leading to excessive gastric acid production. The main treatment goal is to reduce acid secretion and manage symptoms.

The core concept here is that ZES is a neuroendocrine tumor, part of the multiple endocrine neoplasia type 1 (MEN1) syndrome in some cases. The primary treatment for ZES involves controlling acid secretion, often with proton pump inhibitors (PPIs). If the tumor is localized and can be resected, surgery might be an option. However, since most gastrinomas are malignant and metastasize, especially to the liver, surgery isn't always possible. So, medical management is key.

The correct answer is likely a PPI like omeprazole. Let me check the options. The user didn't provide the options, but standard treatments for ZES include PPIs, somatostatin analogs, and in some cases, H2 blockers. For example, if the options were PPIs, H2 blockers, antacids, and surgery, then PPIs would be correct. The mainstay of treatment is PPIs because they inhibit the final common pathway of acid secretion by blocking the H+/K+ ATPase pump in parietal cells. They are more effective than H2 blockers in controlling symptoms and reducing acid output in ZES.

Now, the wrong options: H2 blockers (like ranitidine) are less effective in ZES because they don't inhibit acid secretion as much as PPIs. Antacids are not sufficient for long-term management. Surgery might be an option for localized tumors but isn't the primary treatment. Chemotherapy or targeted therapies are used for metastatic cases but not first-line.

Clinical pearl: Remember that PPIs are the first-line treatment for ZES, and surgical resection is considered if the tumor is localized. Also, ZES is associated with MEN1, so screening for other endocrine tumors is important. The high-yield fact here is the use of PPIs as the mainstay treatment.

**Core Concept**
Zollinger-Ellison syndrome (ZES) is a neuroendocrine tumor disorder characterized by gastrin-secreting gastrinomas, leading to excessive gastric acid production. The primary therapeutic goal is to inhibit acid secretion and manage complications like peptic ulcers and diarrhea. Proton pump inhibitors (PPIs) are the cornerstone due to their ability to block acid secretion at the H+/K+ ATPase pump in parietal cells.

**Why the Correct Answer is Right**
Proton pump inhibitors (e.g., omeprazole) are the first-line treatment for ZES. They irreversibly inhibit the H+/K+ ATPase (proton pump) in gastric parietal cells, effectively reducing gastric acid secretion. This is critical in ZES because gastrinomas cause hypersecretion of gastrin, which stimulates acid production. PPIs are superior to H2-receptor antagonists in controlling acid output and healing ulcers in this condition. Long-term PPI use is often required due to the chronic nature of ZES.

**Why Each

✓ Correct Answer: C. Excision of tumour alone